Middle East Pharmaceutical Industries Company (TADAWUL:4016)

Market Cap	2.42B
Revenue (ttm)	415.54M
Net Income (ttm)	89.88M
Shares Out	20.00M
EPS (ttm)	4.49
PE Ratio	26.93
Forward PE	25.03
Dividend	2.50 (2.07%)
Ex-Dividend Date	May 4, 2025

Volume	5,974
Average Volume	26,271
Open	121.60
Previous Close	121.00
Day's Range	120.60 - 121.80
52-Week Range	107.00 - 144.60
Beta	n/a
RSI	49.44
Earnings Date	Aug 12, 2025

About TADAWUL:4016

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1998
• Employees: 632
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4016

Financial Performance

In 2024, TADAWUL:4016's revenue was 394.00 million, an increase of 16.42% compared to the previous year's 338.44 million. Earnings were 79.85 million, an increase of 21.30%.